Poly (ADP-ribose) polymerases as PET imaging targets for central nervous system diseases
Poly (ADP-ribose) polymerases (PARPs) constitute of 17 members that are associated with divergent cellular processes and play a crucial role in DNA repair, chromatin organization, genome integrity, apoptosis, and inflammation. Multiple lines of evidence have shown that activated PARP1 is associated...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-11-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2022.1062432/full |
| _version_ | 1828134790888423424 |
|---|---|
| author | Jie Tong Baosheng Chen Peng Wen Tan Stephen Kurpiewski Zhengxin Cai |
| author_facet | Jie Tong Baosheng Chen Peng Wen Tan Stephen Kurpiewski Zhengxin Cai |
| author_sort | Jie Tong |
| collection | DOAJ |
| description | Poly (ADP-ribose) polymerases (PARPs) constitute of 17 members that are associated with divergent cellular processes and play a crucial role in DNA repair, chromatin organization, genome integrity, apoptosis, and inflammation. Multiple lines of evidence have shown that activated PARP1 is associated with intense DNA damage and irritating inflammatory responses, which are in turn related to etiologies of various neurological disorders. PARP1/2 as plausible therapeutic targets have attracted considerable interests, and multitudes of PARP1/2 inhibitors have emerged for treating cancer, metabolic, inflammatory, and neurological disorders. Furthermore, PARP1/2 as imaging targets have been shown to detect, delineate, and predict therapeutic responses in many diseases by locating and quantifying the expression levels of PARP1/2. PARP1/2-directed noninvasive positron emission tomography (PET) has potential in diagnosing and prognosing neurological diseases. However, quantitative PARP PET imaging in the central nervous system (CNS) has evaded us due to the challenges of developing blood-brain barrier (BBB) penetrable PARP radioligands. Here, we review PARP1/2's relevance in CNS diseases, summarize the recent progress on PARP PET and discuss the possibilities of developing novel PARP radiotracers for CNS diseases. |
| first_indexed | 2024-04-11T17:40:09Z |
| format | Article |
| id | doaj.art-a61caba4081d44d7831f539705decd51 |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-04-11T17:40:09Z |
| publishDate | 2022-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-a61caba4081d44d7831f539705decd512022-12-22T04:11:31ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2022-11-01910.3389/fmed.2022.10624321062432Poly (ADP-ribose) polymerases as PET imaging targets for central nervous system diseasesJie TongBaosheng ChenPeng Wen TanStephen KurpiewskiZhengxin CaiPoly (ADP-ribose) polymerases (PARPs) constitute of 17 members that are associated with divergent cellular processes and play a crucial role in DNA repair, chromatin organization, genome integrity, apoptosis, and inflammation. Multiple lines of evidence have shown that activated PARP1 is associated with intense DNA damage and irritating inflammatory responses, which are in turn related to etiologies of various neurological disorders. PARP1/2 as plausible therapeutic targets have attracted considerable interests, and multitudes of PARP1/2 inhibitors have emerged for treating cancer, metabolic, inflammatory, and neurological disorders. Furthermore, PARP1/2 as imaging targets have been shown to detect, delineate, and predict therapeutic responses in many diseases by locating and quantifying the expression levels of PARP1/2. PARP1/2-directed noninvasive positron emission tomography (PET) has potential in diagnosing and prognosing neurological diseases. However, quantitative PARP PET imaging in the central nervous system (CNS) has evaded us due to the challenges of developing blood-brain barrier (BBB) penetrable PARP radioligands. Here, we review PARP1/2's relevance in CNS diseases, summarize the recent progress on PARP PET and discuss the possibilities of developing novel PARP radiotracers for CNS diseases.https://www.frontiersin.org/articles/10.3389/fmed.2022.1062432/fullpositron emission tomographyPARP1radiotracersBBBneurodegenerative disease |
| spellingShingle | Jie Tong Baosheng Chen Peng Wen Tan Stephen Kurpiewski Zhengxin Cai Poly (ADP-ribose) polymerases as PET imaging targets for central nervous system diseases Frontiers in Medicine positron emission tomography PARP1 radiotracers BBB neurodegenerative disease |
| title | Poly (ADP-ribose) polymerases as PET imaging targets for central nervous system diseases |
| title_full | Poly (ADP-ribose) polymerases as PET imaging targets for central nervous system diseases |
| title_fullStr | Poly (ADP-ribose) polymerases as PET imaging targets for central nervous system diseases |
| title_full_unstemmed | Poly (ADP-ribose) polymerases as PET imaging targets for central nervous system diseases |
| title_short | Poly (ADP-ribose) polymerases as PET imaging targets for central nervous system diseases |
| title_sort | poly adp ribose polymerases as pet imaging targets for central nervous system diseases |
| topic | positron emission tomography PARP1 radiotracers BBB neurodegenerative disease |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2022.1062432/full |
| work_keys_str_mv | AT jietong polyadpribosepolymerasesaspetimagingtargetsforcentralnervoussystemdiseases AT baoshengchen polyadpribosepolymerasesaspetimagingtargetsforcentralnervoussystemdiseases AT pengwentan polyadpribosepolymerasesaspetimagingtargetsforcentralnervoussystemdiseases AT stephenkurpiewski polyadpribosepolymerasesaspetimagingtargetsforcentralnervoussystemdiseases AT zhengxincai polyadpribosepolymerasesaspetimagingtargetsforcentralnervoussystemdiseases |